WO2001060778A3 - Aspirin-triggered lipid mediators - Google Patents
Aspirin-triggered lipid mediators Download PDFInfo
- Publication number
- WO2001060778A3 WO2001060778A3 PCT/US2001/005196 US0105196W WO0160778A3 WO 2001060778 A3 WO2001060778 A3 WO 2001060778A3 US 0105196 W US0105196 W US 0105196W WO 0160778 A3 WO0160778 A3 WO 0160778A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aspirin
- lipid mediators
- triggered lipid
- triggered
- mediators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60124256T DE60124256T3 (en) | 2000-02-16 | 2001-02-16 | ASPIRIN-RELATED LIPID MEDIATORS |
CA2400462A CA2400462C (en) | 2000-02-16 | 2001-02-16 | Aspirin-triggered lipid mediators |
EP01910912A EP1296923B3 (en) | 2000-02-16 | 2001-02-16 | Aspirin-triggered lipid mediators |
IL15129901A IL151299A0 (en) | 2000-02-16 | 2001-02-16 | Aspirin-triggered lipid mediators |
MXPA02007915A MXPA02007915A (en) | 2000-02-16 | 2001-02-16 | Aspirin triggered lipid mediators. |
AU2001238468A AU2001238468B2 (en) | 2000-02-16 | 2001-02-16 | Aspirin-triggered lipid mediators |
JP2001559832A JP4932116B2 (en) | 2000-02-16 | 2001-02-16 | Aspirin-induced lipid mediator |
AU3846801A AU3846801A (en) | 2000-02-16 | 2001-02-16 | Aspirin-triggered lipid mediators |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18307800P | 2000-02-16 | 2000-02-16 | |
US60/183,078 | 2000-02-16 | ||
US23881400P | 2000-10-06 | 2000-10-06 | |
US60/238,814 | 2000-10-06 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001060778A2 WO2001060778A2 (en) | 2001-08-23 |
WO2001060778A9 WO2001060778A9 (en) | 2002-10-24 |
WO2001060778A3 true WO2001060778A3 (en) | 2003-01-16 |
Family
ID=26878731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/005196 WO2001060778A2 (en) | 2000-02-16 | 2001-02-16 | Aspirin-triggered lipid mediators |
Country Status (12)
Country | Link |
---|---|
US (5) | US6670396B2 (en) |
EP (2) | EP1296923B3 (en) |
JP (5) | JP4932116B2 (en) |
CN (4) | CN1202068C (en) |
AT (2) | ATE344226T1 (en) |
AU (4) | AU2001238468B2 (en) |
CA (1) | CA2400462C (en) |
DE (2) | DE60144401D1 (en) |
HK (1) | HK1105948A1 (en) |
IL (1) | IL151299A0 (en) |
MX (1) | MXPA02007915A (en) |
WO (1) | WO2001060778A2 (en) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1296923B3 (en) * | 2000-02-16 | 2012-04-11 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
EP1268393A2 (en) | 2000-03-20 | 2003-01-02 | Trustees Of Boston University | Lipoxin analogs and methods for the treatment of periodontal disease |
ITMI20010129A1 (en) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE |
AU2002255627B2 (en) * | 2001-02-27 | 2008-01-17 | The Regents Of The University Of Michigan | Use of natural EGFR inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor |
DK1406698T3 (en) * | 2001-03-02 | 2009-02-09 | Brigham & Womens Hospital | Lipoxin analogs as novel inhibitors of angiogenesis |
DE60236467D1 (en) | 2001-03-02 | 2010-07-01 | Brigham And Women S Hospital B | Lipoxin analogues as novel restenosis inhibitors |
GB0111282D0 (en) * | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
US20040176451A1 (en) * | 2001-06-18 | 2004-09-09 | Tadakazu Tamai | Pparg agonistic medicinal compositions |
ITMI20012384A1 (en) | 2001-11-12 | 2003-05-12 | Quatex Nv | USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS |
CA2467580C (en) * | 2001-12-18 | 2012-10-30 | Brigham And Women's Hospital | Use of lipoxin analogs to promote cell defense against gram-negative infections |
US7030159B2 (en) * | 2001-12-18 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs |
US8481772B2 (en) | 2002-04-01 | 2013-07-09 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
US7582785B2 (en) | 2002-04-01 | 2009-09-01 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
EP2022775B1 (en) * | 2002-04-01 | 2014-10-15 | University of Southern California | Trihydroxy polyunsaturated eicosanoids |
US7902257B2 (en) | 2002-04-01 | 2011-03-08 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid |
AU2003238240A1 (en) * | 2002-06-17 | 2003-12-31 | Resolvyx Pharmaceuticals | ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE |
EP2216318B1 (en) | 2002-08-12 | 2018-10-10 | Brigham And Women's Hospital | Resolvins: Biotemplates for therapeutic interventions |
US7759395B2 (en) | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
CA2499501A1 (en) * | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
WO2004078143A2 (en) * | 2003-03-05 | 2004-09-16 | The Brigham And Women's Hospital Inc. | Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
ES2349927T3 (en) * | 2003-07-07 | 2011-01-13 | Hill's Pet Nutrition, Inc. | COMPOSITIONS TO IMPROVE THE OXIDATIVE STATE IN CATS. |
US20050238589A1 (en) * | 2004-04-14 | 2005-10-27 | Van Dyke Thomas E | Methods and compositions for preventing or treating periodontal diseases |
US20060002985A1 (en) * | 2004-07-02 | 2006-01-05 | Zicker Steven C | Compositions and methods for decreasing age-related deterioration in mental activities in companion animals |
EP2801354B1 (en) * | 2004-10-08 | 2017-02-08 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
US20090318394A1 (en) * | 2004-11-19 | 2009-12-24 | Julie Nauroth | Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same |
KR20070090928A (en) * | 2004-11-19 | 2007-09-06 | 마텍 바이오싸이언스스 코포레이션 | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
US7893106B2 (en) * | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
US20060293288A1 (en) * | 2005-01-07 | 2006-12-28 | Serhan Charles N | Use of resolvins to treat gastrointestinal diseases |
US20060194723A1 (en) * | 2005-02-28 | 2006-08-31 | Rabinoff Michael D | Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement |
US8273792B2 (en) | 2005-10-03 | 2012-09-25 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers |
WO2007061783A1 (en) | 2005-11-18 | 2007-05-31 | Trustees Of Boston University | Treatment and prevention of bone loss using resolvins |
US20090320148A1 (en) * | 2006-01-31 | 2009-12-24 | Martek Biosciences Corporation | Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same |
AU2007243282A1 (en) * | 2006-04-28 | 2007-11-08 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of cardiovascular disease |
CN101528218A (en) * | 2006-07-19 | 2009-09-09 | 雷索维克斯药品公司 | Compositions and methods for the treatment of mucositis |
WO2008057283A2 (en) * | 2006-10-26 | 2008-05-15 | Resolvyx Pharmaceuticals, Inc. | Use of resolvins for inhibition of bone loss |
WO2008070129A2 (en) * | 2006-12-05 | 2008-06-12 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of inflammatory disease |
WO2009006668A1 (en) * | 2007-02-05 | 2009-01-15 | Children, Youth And Women's Health Service | Modulators of antigen-dependent t cell proliferation |
US20110190389A1 (en) * | 2007-02-20 | 2011-08-04 | Linda Arterburn | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
US8324277B2 (en) | 2007-08-01 | 2012-12-04 | University of Pittsburgh—of the Commonwealth System of Higher Education | Nitrated-fatty acids modulation of type II diabetes |
WO2009038671A2 (en) * | 2007-09-14 | 2009-03-26 | Resolvyx Pharmaceuticals, Inc. | Oxylipin compounds for treating autoimmune diseases |
AU2008312006B2 (en) * | 2007-10-12 | 2013-12-12 | Resolvyx Pharmaceuticals, Inc. | Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxyliptin compounds for the treatment of ophthalmic conditions |
US20110027841A1 (en) * | 2007-12-21 | 2011-02-03 | Martek Biosciences Corporation | Method for preparation of oxylipins |
EP2280928B1 (en) | 2008-05-01 | 2018-07-25 | Complexa Inc. | Vinyl substituted fatty acids |
US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
JPWO2010021385A1 (en) * | 2008-08-22 | 2012-01-26 | 持田製薬株式会社 | ANCA-related vasculitis treatment |
EP2344441B1 (en) | 2008-09-16 | 2016-02-17 | The Brigham And Women's Hospital Inc. | 7,14-dihydroxy-docosahexaenoic acid compounds |
US20110190242A1 (en) * | 2008-09-23 | 2011-08-04 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of inflammatory disease |
WO2010095706A1 (en) | 2009-02-20 | 2010-08-26 | 国立大学法人東京大学 | Novel anti-inflammatory compounds |
GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
WO2011014261A1 (en) * | 2009-07-31 | 2011-02-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Fatty acids as anti-inflammatory agents |
WO2011041639A2 (en) | 2009-10-02 | 2011-04-07 | Miller Raymond A | Heteroatom containing substituted fatty acids |
US20130137767A1 (en) * | 2010-02-02 | 2013-05-30 | Dsm Ip Assets B.V. | Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid |
WO2012023254A1 (en) * | 2010-08-19 | 2012-02-23 | 国立大学法人 東京大学 | Novel anti-inflammatory metabolite derived from omega-3-type fatty acid |
EP2744491B1 (en) | 2011-08-19 | 2020-07-29 | The University of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
FR2979824A1 (en) * | 2011-09-13 | 2013-03-15 | Vetinnov | Kit, useful for preventing and/or treating inflammatory diseases e.g. osteoarthritis, comprises dosing units containing nutritional/pharmaceutical human/veterinary composition and combination of docosahexaenoic acid and salicylic acid |
JP5969186B2 (en) * | 2011-09-15 | 2016-08-17 | 出光興産株式会社 | GPR119 agonist and insulin secretagogue, hypoglycemic agent and diabetes treatment or prevention agent containing the same |
WO2013044176A2 (en) * | 2011-09-23 | 2013-03-28 | University Of Southern California | Methods and compositions for the treatment of ischemic stroke |
EP2814479B1 (en) | 2012-02-15 | 2019-09-04 | Anida Pharma Inc. | Methods of treating amyotrophic lateral sclerosis |
ES2946109T3 (en) | 2012-05-10 | 2023-07-12 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural specialized pro-resolving mediators and their precursors |
GB201213484D0 (en) * | 2012-07-30 | 2012-09-12 | Dignity Sciences Ltd | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
CA3050298A1 (en) | 2012-08-24 | 2014-02-27 | Sun Pharma Global Fze | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions |
GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
US11058659B2 (en) | 2013-02-22 | 2021-07-13 | University Of Southern California | Methods and compositions for the treatment of ophalmic diseases and disorders |
JP6295278B2 (en) | 2013-02-28 | 2018-03-14 | アニダ ファーマ インコーポレイテッド | How to treat ototoxicity |
WO2015071766A1 (en) | 2013-11-15 | 2015-05-21 | Dignity Sciences Limited | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids |
KR20160132372A (en) * | 2014-01-10 | 2016-11-18 | 디그너티 사이언스 리미티드 | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
BR112016028518A2 (en) | 2014-06-04 | 2017-08-22 | Dignity Sciences Ltd | pharmaceutical compositions comprising dgla and use thereof |
MA41120A (en) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | COMPOSITIONS INCLUDING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING THEM |
CN114377138A (en) | 2015-03-18 | 2022-04-22 | 福塞斯儿童牙科医院 | Method for stabilizing atherosclerotic plaques using lipoxins, resolvins and analogs thereof |
EP3865484B1 (en) | 2015-07-07 | 2023-11-08 | H. Lundbeck A/S | Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases |
CN112245420A (en) * | 2015-07-21 | 2021-01-22 | 艾菲穆恩有限公司 | Compositions comprising 15-HEPE for treating or preventing cancer and neurological diseases |
WO2017041094A1 (en) | 2015-09-03 | 2017-03-09 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same |
BR112018006687A2 (en) | 2015-10-02 | 2018-10-09 | Complexa Inc | disease prevention, treatment and reversal using therapeutically effective amounts of active fatty acids |
WO2017077528A2 (en) | 2015-11-02 | 2017-05-11 | Salzman Lovelace Investments, Ltd. | Methods and pharmaceutical compositions for treatment of lung inflammation |
FI3373976T3 (en) | 2015-11-10 | 2024-03-25 | Sun Pharmaceutical Ind Ltd | Topical formulations and uses thereof |
WO2017205582A1 (en) | 2016-05-27 | 2017-11-30 | Forsyth Dental Infirmary For Children | Compositions and methods of treating cancer using lipid agonists and receptors thereof |
CA3026264A1 (en) | 2016-06-03 | 2017-12-07 | Thetis Pharmaceuticals Llc | Compositions and methods relating to salts of specialized pro-resolving mediators |
CN105924338B (en) * | 2016-06-17 | 2019-03-01 | 中科瑞奥能源科技股份有限公司 | Butanol solvent recovery technology from vent gas and system |
WO2017223447A1 (en) | 2016-06-23 | 2017-12-28 | The Regents Of The University Of Michigan | 12(s)-hydroxyeicosatrienoic acid compounds and their use as therapeutic agents |
CA3055093A1 (en) | 2017-03-09 | 2018-09-13 | University Health Network | Lipoxin and lipoxin analogue mediated neuroprotection and treatments |
WO2019182191A1 (en) * | 2018-03-21 | 2019-09-26 | 경북대학교 산학협력단 | Pharmaceutical composition for prevention or treatment of neurodegenerative disease and comprising cox2-acetylating agent as active ingredient |
WO2020076578A1 (en) | 2018-10-09 | 2020-04-16 | University Of Rochester | Treatment of vulvovaginal disorders |
BR112021010335A2 (en) * | 2018-11-30 | 2021-11-16 | Evonik Operations Gmbh | Preparation comprising a probiotic strain and a polyunsaturated fatty acid component |
EP3946308A4 (en) * | 2019-04-04 | 2022-12-14 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use |
EP4032914A4 (en) * | 2019-09-20 | 2023-10-18 | Kyungpook National University Industry-Academic Cooperation Foundation | Antibody for detecting acetylation of cox2 protein, and uses thereof |
IL297114A (en) * | 2020-04-03 | 2022-12-01 | Afimmune Ltd | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases |
CN112511569B (en) * | 2021-02-07 | 2021-05-11 | 杭州筋斗腾云科技有限公司 | Method and system for processing network resource access request and computer equipment |
WO2023168245A2 (en) | 2022-03-03 | 2023-09-07 | Thetis Pharmaceuticals Llc | Cyclodextrin complexes of specialized proresolving mediators |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666701A (en) * | 1985-03-19 | 1987-05-19 | Efamol Limited | Pharmaceutical and dietary compositions |
US4810424A (en) * | 1987-10-09 | 1989-03-07 | The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados |
WO1991016914A1 (en) * | 1990-05-07 | 1991-11-14 | Bockow Barry I | Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof |
JPH05186342A (en) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | Antiinflammatory agent having immunoregulatory action |
US5409955A (en) * | 1993-05-13 | 1995-04-25 | Bockow; Barry I. | Compositions and methods for inhibiting uterine contractility |
US5411988A (en) * | 1993-10-27 | 1995-05-02 | Bockow; Barry I. | Compositions and methods for inhibiting inflammation and adhesion formation |
US5709855A (en) * | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
WO1998046588A2 (en) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
US6201022B1 (en) * | 1997-03-27 | 2001-03-13 | Myorx, Inc. | Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US466701A (en) | 1892-01-05 | Hiram ezkiel payne | ||
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
GB2033745B (en) | 1978-05-26 | 1983-08-17 | Wellcome Found | Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions |
US4442099A (en) | 1981-11-27 | 1984-04-10 | Research Corporation | Leukotriene analogues |
US4567290A (en) | 1981-11-27 | 1986-01-28 | Research Corporation | Leukotriene analogues |
US4576758A (en) | 1984-06-01 | 1986-03-18 | The Upjohn Company | Anti-inflammatory lipoxin B analogs |
US4759880A (en) | 1984-09-27 | 1988-07-26 | Research Corporation | Alkanoarachidonic acids |
US4710521A (en) | 1986-07-25 | 1987-12-01 | The Celotex Corporation | Catalyst mixtures for polyisocyanurate foam |
US5136501A (en) | 1989-05-26 | 1992-08-04 | Reuters Limited | Anonymous matching system |
JPH0425036A (en) | 1990-05-16 | 1992-01-28 | Mitsubishi Electric Corp | Microwave semiconductor device |
US5650435A (en) | 1991-04-01 | 1997-07-22 | Madara; James L. | Modulation of inflammation related to columnar epithelia |
US5087790A (en) | 1991-06-12 | 1992-02-11 | University Of Southern California | Method for olefination of carbonyl compounds using titanocene derivatives |
CA2112399C (en) | 1991-06-24 | 2004-06-29 | Antonio Ferrante | Methods and compositions for treating malaria and other diseases |
US5177046A (en) | 1991-09-20 | 1993-01-05 | Air Products And Chemicals, Inc. | Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes |
US5441951A (en) | 1994-06-15 | 1995-08-15 | Brigham & Women's Hospital | Lipoxin compounds |
US6887901B1 (en) | 1993-06-15 | 2005-05-03 | Brigham & Women's Hospital, Inc. | Lipoxin compounds and their use in treating cell proliferative disorders |
US6048897A (en) | 1993-06-15 | 2000-04-11 | Brigham And Women's Hospital | Lipoxin compounds and their use in treating cell proliferative disorders |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
JP2536436B2 (en) | 1993-11-19 | 1996-09-18 | 日本電気株式会社 | Mold type semiconductor device |
US6030917A (en) | 1996-07-23 | 2000-02-29 | Symyx Technologies, Inc. | Combinatorial synthesis and analysis of organometallic compounds and catalysts |
US5752238A (en) | 1994-11-03 | 1998-05-12 | Intel Corporation | Consumer-driven electronic information pricing mechanism |
US5594732A (en) | 1995-03-03 | 1997-01-14 | Intecom, Incorporated | Bridging and signalling subsystems and methods for private and hybrid communications systems including multimedia systems |
US5801280A (en) | 1995-04-07 | 1998-09-01 | Sumitomo Chemical Company, Limited | Processes for preparing optically active alcohols and optically active amines |
US5845265A (en) | 1995-04-26 | 1998-12-01 | Mercexchange, L.L.C. | Consignment nodes |
US5756789A (en) | 1995-06-08 | 1998-05-26 | Texaco, Inc. | Synthesis of metal--containing aluminophosphates with layered structure |
CA2182851A1 (en) | 1995-08-15 | 1997-02-16 | August Masaru Watanabe | Method for treating substance abuse withdrawal |
US5870717A (en) | 1995-11-13 | 1999-02-09 | International Business Machines Corporation | System for ordering items over computer network using an electronic catalog |
US5789441A (en) * | 1996-02-15 | 1998-08-04 | Virocell Inc. | Leukotriene B4 as an antiviral and anti-neoplastic agent |
ES2311571T3 (en) | 1996-04-12 | 2009-02-16 | G.D. Searle Llc | BENCENOSULFONAMIDE DERIVATIVES SUBSTITUTED AS COX-2 INHIBITORS PROFARMS. |
US5878400A (en) | 1996-06-17 | 1999-03-02 | Trilogy Development Group, Inc. | Method and apparatus for pricing products in multi-level product and organizational groups |
US5842040A (en) | 1996-06-18 | 1998-11-24 | Storage Technology Corporation | Policy caching method and apparatus for use in a communication device based on contents of one data unit in a subset of related data units |
US6602817B1 (en) | 1998-10-23 | 2003-08-05 | University Of Southern California | Combination approach to chiral reagents or catalysts having amine or amino alcohol ligands |
CA2259203C (en) | 1996-06-28 | 2008-04-29 | Nicos A. Petasis | Method for the synthesis of amines and amino acids with organoboron derivatives |
US5890138A (en) | 1996-08-26 | 1999-03-30 | Bid.Com International Inc. | Computer auction system |
US5861399A (en) | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
US5896379A (en) | 1996-08-26 | 1999-04-20 | Motorola, Inc. | Network node for packet switching with selective data processing and method therefor |
US5912006A (en) | 1996-08-28 | 1999-06-15 | Eboc, Inc. | Compositions and methods for alleviating discomforting menstrual pain |
US5946467A (en) | 1996-09-20 | 1999-08-31 | Novell, Inc. | Application-level, persistent packeting apparatus and method |
US20020055539A1 (en) | 1996-10-02 | 2002-05-09 | Bockow Barry I. | Compositions and methods for treating cardiovascular conditions |
US6008205A (en) | 1997-04-04 | 1999-12-28 | The Brigham & Women's Hospital, Inc. | Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses |
US6428990B1 (en) | 1997-04-11 | 2002-08-06 | Abbott Laboratories | Human desaturase gene and uses thereof |
US5878423A (en) | 1997-04-21 | 1999-03-02 | Bellsouth Corporation | Dynamically processing an index to create an ordered set of questions |
US6030715A (en) | 1997-10-09 | 2000-02-29 | The University Of Southern California | Azlactone-related dopants in the emissive layer of an OLED |
US6259699B1 (en) | 1997-12-30 | 2001-07-10 | Nexabit Networks, Llc | System architecture for and method of processing packets and/or cells in a common switch |
EP1075252A2 (en) | 1998-05-07 | 2001-02-14 | ELAN CORPORATION, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
US6377937B1 (en) | 1998-05-28 | 2002-04-23 | Paskowitz Associates | Method and system for more effective communication of characteristics data for products and services |
US6069109A (en) | 1998-07-01 | 2000-05-30 | Union Carbide Chemicals & Plastics Technology Corporation | Process for the production of half-sandwich transition metal based catalyst precursors |
US6336138B1 (en) | 1998-08-25 | 2002-01-01 | Hewlett-Packard Company | Template-driven approach for generating models on network services |
US6336105B1 (en) | 1998-11-16 | 2002-01-01 | Trade Access Inc. | System and method for representing data and providing electronic non-repudiation in a negotiations system |
DE19855426A1 (en) | 1998-12-02 | 2000-06-08 | Wolfgang Langhoff | Agents for the therapy and prophylaxis of rheumatic-arthritic diseases and for the prophylaxis of cardiovascular diseases |
US6272474B1 (en) | 1999-02-08 | 2001-08-07 | Crisostomo B. Garcia | Method for monitoring and trading stocks via the internet displaying bid/ask trade bars |
US6397212B1 (en) | 1999-03-04 | 2002-05-28 | Peter Biffar | Self-learning and self-personalizing knowledge search engine that delivers holistic results |
EP2236140A1 (en) | 1999-03-18 | 2010-10-06 | The Brigham and Women's Hospital, Inc. | Regulation of phospholipase D activity |
ATE310512T1 (en) | 1999-03-18 | 2005-12-15 | Brigham & Womens Hospital | USE OF LIPOXINS TO INHIBIT TNF-ALPHA INITIATED COUNTERREACTION |
US6271435B1 (en) | 1999-03-18 | 2001-08-07 | Brigham & Women's Hospital, Inc. | Leukotriene B4 receptor transgenic mice |
CA2365204C (en) | 1999-03-18 | 2009-10-27 | Brigham And Women's Hospital | Lipoxin compounds and their use |
US6427132B1 (en) | 1999-08-31 | 2002-07-30 | Accenture Llp | System, method and article of manufacture for demonstrating E-commerce capabilities via a simulation on a network |
US6415270B1 (en) | 1999-09-03 | 2002-07-02 | Omnihub, Inc. | Multiple auction coordination method and system |
EP1296923B3 (en) | 2000-02-16 | 2012-04-11 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
EP1268393A2 (en) | 2000-03-20 | 2003-01-02 | Trustees Of Boston University | Lipoxin analogs and methods for the treatment of periodontal disease |
US6473314B1 (en) | 2000-08-03 | 2002-10-29 | Powerwave Technologies, Inc. | RF power amplifier assembly employing multi-layer RF blocking filter |
US20020074162A1 (en) | 2000-12-15 | 2002-06-20 | Bor-Ray Su | Substrate layout method and structure for reducing cross talk of adjacent signals |
DK1406698T3 (en) | 2001-03-02 | 2009-02-09 | Brigham & Womens Hospital | Lipoxin analogs as novel inhibitors of angiogenesis |
US20040044028A1 (en) | 2001-03-30 | 2004-03-04 | Obukowicz Mark G. | Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer |
CA2465117C (en) | 2001-11-06 | 2012-01-03 | Brigham And Women's Hospital, Inc. | Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
US7030159B2 (en) | 2001-12-18 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs |
CA2467580C (en) | 2001-12-18 | 2012-10-30 | Brigham And Women's Hospital | Use of lipoxin analogs to promote cell defense against gram-negative infections |
EP2022775B1 (en) * | 2002-04-01 | 2014-10-15 | University of Southern California | Trihydroxy polyunsaturated eicosanoids |
US7902257B2 (en) | 2002-04-01 | 2011-03-08 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid |
US7582785B2 (en) | 2002-04-01 | 2009-09-01 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
AU2003238240A1 (en) | 2002-06-17 | 2003-12-31 | Resolvyx Pharmaceuticals | ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE |
US7759395B2 (en) | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
EP2216318B1 (en) | 2002-08-12 | 2018-10-10 | Brigham And Women's Hospital | Resolvins: Biotemplates for therapeutic interventions |
WO2004078143A2 (en) | 2003-03-05 | 2004-09-16 | The Brigham And Women's Hospital Inc. | Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
WO2005013908A2 (en) | 2003-08-05 | 2005-02-17 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration |
US20050238589A1 (en) | 2004-04-14 | 2005-10-27 | Van Dyke Thomas E | Methods and compositions for preventing or treating periodontal diseases |
US20060293288A1 (en) | 2005-01-07 | 2006-12-28 | Serhan Charles N | Use of resolvins to treat gastrointestinal diseases |
US8273792B2 (en) | 2005-10-03 | 2012-09-25 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers |
CN101528218A (en) | 2006-07-19 | 2009-09-09 | 雷索维克斯药品公司 | Compositions and methods for the treatment of mucositis |
-
2001
- 2001-02-16 EP EP01910912A patent/EP1296923B3/en not_active Expired - Lifetime
- 2001-02-16 AU AU2001238468A patent/AU2001238468B2/en not_active Expired
- 2001-02-16 EP EP06022386A patent/EP1762557B1/en not_active Expired - Lifetime
- 2001-02-16 CN CNB018081282A patent/CN1202068C/en not_active Expired - Fee Related
- 2001-02-16 CA CA2400462A patent/CA2400462C/en not_active Expired - Lifetime
- 2001-02-16 DE DE60144401T patent/DE60144401D1/en not_active Expired - Lifetime
- 2001-02-16 DE DE60124256T patent/DE60124256T3/en not_active Expired - Lifetime
- 2001-02-16 AU AU3846801A patent/AU3846801A/en active Pending
- 2001-02-16 CN CN2006101003106A patent/CN1951899B/en not_active Expired - Fee Related
- 2001-02-16 US US09/785,866 patent/US6670396B2/en not_active Expired - Lifetime
- 2001-02-16 WO PCT/US2001/005196 patent/WO2001060778A2/en active IP Right Grant
- 2001-02-16 IL IL15129901A patent/IL151299A0/en unknown
- 2001-02-16 CN CNB200510054411XA patent/CN100357244C/en not_active Expired - Fee Related
- 2001-02-16 JP JP2001559832A patent/JP4932116B2/en not_active Expired - Lifetime
- 2001-02-16 CN CN201010507698.8A patent/CN102010324B/en not_active Expired - Fee Related
- 2001-02-16 AT AT01910912T patent/ATE344226T1/en not_active IP Right Cessation
- 2001-02-16 MX MXPA02007915A patent/MXPA02007915A/en active IP Right Grant
- 2001-02-16 AT AT06022386T patent/ATE504557T1/en not_active IP Right Cessation
-
2003
- 2003-09-12 US US10/663,061 patent/US7053230B2/en not_active Expired - Lifetime
-
2006
- 2006-01-18 US US11/334,330 patent/US7709669B2/en not_active Expired - Lifetime
- 2006-10-05 AU AU2006225252A patent/AU2006225252B2/en not_active Expired
-
2007
- 2007-10-18 HK HK07111255.0A patent/HK1105948A1/en not_active IP Right Cessation
-
2008
- 2008-12-18 US US12/338,240 patent/US7737178B2/en not_active Expired - Lifetime
-
2009
- 2009-05-26 AU AU2009202071A patent/AU2009202071B2/en not_active Expired
-
2010
- 2010-02-17 US US12/707,317 patent/US8349896B2/en not_active Expired - Lifetime
- 2010-06-14 JP JP2010134989A patent/JP2010248213A/en active Pending
-
2014
- 2014-07-08 JP JP2014140321A patent/JP5973503B2/en not_active Expired - Lifetime
-
2015
- 2015-07-08 JP JP2015137034A patent/JP2016006057A/en not_active Withdrawn
-
2019
- 2019-02-22 JP JP2019030694A patent/JP2019108348A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666701A (en) * | 1985-03-19 | 1987-05-19 | Efamol Limited | Pharmaceutical and dietary compositions |
US4810424A (en) * | 1987-10-09 | 1989-03-07 | The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados |
WO1991016914A1 (en) * | 1990-05-07 | 1991-11-14 | Bockow Barry I | Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof |
JPH05186342A (en) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | Antiinflammatory agent having immunoregulatory action |
US5409955A (en) * | 1993-05-13 | 1995-04-25 | Bockow; Barry I. | Compositions and methods for inhibiting uterine contractility |
US5411988A (en) * | 1993-10-27 | 1995-05-02 | Bockow; Barry I. | Compositions and methods for inhibiting inflammation and adhesion formation |
US5709855A (en) * | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
US6201022B1 (en) * | 1997-03-27 | 2001-03-13 | Myorx, Inc. | Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid |
WO1998046588A2 (en) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
Non-Patent Citations (7)
Title |
---|
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KARANIAN, J. ET AL: "Physiological functions of hydroxy-docosahexaenoic acid", XP002200246, Database accession no. 1993:405773 * |
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002200247, Database accession no. 1992:405773 * |
DATABASE WPI Section Ch Week 199334, Derwent World Patents Index; Class B05, AN 1993-269748, XP002184773 * |
DE MONTARBY: "Synthèses stéréosélective de métabolites hydroxylés d'acides gras polyinsaturés", BULLETIN DE LA SOCIÉTÉ CHIMIQUE DE FRANCE, no. 3, 1989, pages 419 - 432, XP002200244 * |
HILL, E. M.; HOLLAND, D. L.: "Identification and egg hatching activity of monohydroxy fatty acid eicosanoids in the barnacle Balanus balanoides", PROC. R. SOC. LONDON, SER. B, vol. 247, no. 1318, 1992, pages 41 - 46 * |
KATO, T. ET AL: "Production of hydroxy unsaturated fatty acids using crude lipoxygenase obtained from infected rice plants", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 69, no. 6, 1996, pages 1663 - 1666, XP002200251 * |
YAMANE, M. ET AL: "Docosahexaenoic/arachiconic acid omega-hydroxylation system and differentiation in the human colonic adenocarcinoma cell line, Caco-2", CANCER LETTERS, vol. 122, 1998, pages 51 - 59, XP002200245 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001060778A3 (en) | Aspirin-triggered lipid mediators | |
AU2002356759A1 (en) | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents | |
MXPA03004017A (en) | Method for the treatment of inflammation. | |
WO2003014156A3 (en) | NEUREGULIN-β ISOFORMS ASSOCIATED WITH NEURONAL PROCESSES | |
AU4453301A (en) | Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis | |
ZA200201050B (en) | The fortification of sugar. | |
AU2002343328A1 (en) | Therapeutic agents that inhibit the tup1 pathway | |
AU2002324469A1 (en) | Substituted-heteroaryl-7-aza(2.2.1)bicycloheptanes for the treatment of disease | |
IT1318631B1 (en) | PROCEDURE FOR THE PRODUCTION OF ALFA-OLEFINE. | |
IT1321293B1 (en) | PROCEDURE FOR THE PREPARATION OF PENTENOIC ESTERS. | |
ZA200004599B (en) | Process for maintaining the stability of the fortification. | |
IT1311985B1 (en) | PROCEDURE FOR THE PREPARATION OF ISOSORBIDE-5-MONONITRATE. | |
TH9901002909A (en) | The patent has not yet been announced. | |
TH9901001679A (en) | The patent has not yet been announced. | |
TH9902000917EX (en) | The patent has not yet been announced. | |
TH9901001508A (en) | The patent has not yet been announced. | |
TH9901002892A (en) | The patent has not yet been announced. | |
TH9901002881A (en) | The patent has not yet been announced. | |
TH9901002723A (en) | The patent has not yet been announced. | |
TH9901002661A (en) | The patent has not yet been announced. | |
TH9901002496A (en) | The patent has not yet been announced. | |
TH9901002436A (en) | The patent has not yet been announced. | |
TH9901002418A (en) | The patent has not yet been announced. | |
TH9901002270A (en) | The patent has not yet been announced. | |
TH9901002218A (en) | The patent has not yet been announced. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2400462 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2001 559832 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/007915 Country of ref document: MX Ref document number: 151299 Country of ref document: IL Ref document number: 2001238468 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/1057/KOL Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001910912 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018081282 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/26-26/26, DRAWINGS, REPLACED BY NEW PAGES 1/51-51/51; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001910912 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001910912 Country of ref document: EP |